CTIC — CTI Biopharma Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.20bn
- $1.26bn
- $53.95m
Annual income statement for CTI Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 26.3 | 3.35 | 0 | 0 | 53.9 |
| Cost of Revenue | |||||
| Gross Profit | 25.4 | — | — | — | 50.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 59.2 | 44.1 | 51.5 | 95.5 | 134 |
| Operating Profit | -32.9 | -40.7 | -51.5 | -95.5 | -79.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -29.4 | -40 | -52.5 | -97.9 | -93 |
| Net Income After Taxes | -29.4 | -40 | -52.5 | -97.9 | -93 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -29.3 | -40 | -52.5 | -97.9 | -93 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -29.4 | -40 | -52.5 | -97.9 | -93 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.513 | -0.677 | -0.625 | -1.08 | -0.811 |